LAMICTAL
ARIPIPRAZOLE
CARBAMAZEPINE
LITHIUM
OLANZAPINE
QUETIAPINE
RISPERIDONE
SSRI
TOPIRAMATE
VALPROATE
ZIPRASIDONE
OLANZAPINE
SUPPORTING DATA
Marketing information
Key claims
Reduced relapse rate
Longer time to relapse
At least as effective as lithium
Supporting data
OFC in bipolar depression
No treatment-emergent mania
Improvements in HR-Qol
Fewer drop-outs than lithium
No QTc prolongation
Usage
Country information
References
Supported by GSK.
(c) 2004 Excerpta Medica
All rights reserved.
Disclaimer
1.
Olanzapine vs lithium for prevention of relapse
Author: Tohen, et al. Title: Olanzapine versus lithium in relapse prevention in bipolar...
